StockNews.com Upgrades Puma Biotechnology to Strong-Buy
PBYI Stock | USD 3.39 0.16 4.95% |
Under 58% of all Puma Biotechnology's traders are looking to take a long position. The analysis of the overall investor sentiment regarding Puma Biotechnology suggests that some traders are interested. Puma Biotechnology's investing sentiment shows overall attitude of investors towards Puma Biotechnology.
Puma |
StockNews.com upgraded shares of Puma Biotechnology from a buy rating to a strong-buy rating in a research report sent to investors on Wednesday. Separately, HC Wainwright reiterated a buy rating and set a 7.00 target price on shares of Puma Biotechnology in a research note on Friday, August 2nd. View Our
Read at thelincolnianonline.com
Puma Biotechnology Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Puma Biotechnology can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Puma Biotechnology Fundamental Analysis
We analyze Puma Biotechnology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Puma Biotechnology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Puma Biotechnology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
EBITDA
EBITDA Comparative Analysis
Puma Biotechnology is currently under evaluation in ebitda category among its peers. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Puma Biotechnology Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Puma Biotechnology stock to make a market-neutral strategy. Peer analysis of Puma Biotechnology could also be used in its relative valuation, which is a method of valuing Puma Biotechnology by comparing valuation metrics with similar companies.
Peers
Puma Biotechnology Related Equities
HEPA | Hepion Pharmaceuticals | 4.69 | ||||
ARVN | Arvinas | 2.85 | ||||
HRTX | Heron Therapeuti | 2.59 | ||||
TSVT | 2Seventy Bio | 0.76 | ||||
CRNX | Crinetics Pharmaceuticals | 0.81 | ||||
IOVA | Iovance Biotherapeutics | 0.85 | ||||
MDGL | Madrigal Pharmaceuticals | 0.98 | ||||
RARE | Ultragenyx | 1.04 | ||||
KURA | Kura Oncology | 1.16 | ||||
RVMD | Revolution Medicines | 1.25 | ||||
MGNX | MacroGenics | 1.37 | ||||
PTCT | PTC Therapeutics | 2.73 | ||||
VKTX | Viking Therapeutics | 2.88 | ||||
CHRS | Coherus BioSciences | 3.17 | ||||
SRPT | Sarepta Therapeutics | 3.33 | ||||
LRMR | Larimar Therapeutics | 4.67 |
Complementary Tools for Puma Stock analysis
When running Puma Biotechnology's price analysis, check to measure Puma Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Puma Biotechnology is operating at the current time. Most of Puma Biotechnology's value examination focuses on studying past and present price action to predict the probability of Puma Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Puma Biotechnology's price. Additionally, you may evaluate how the addition of Puma Biotechnology to your portfolios can decrease your overall portfolio volatility.
Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets |